AbbVie ( NYSE: ABBV) shares snapped seven straight sessions of gains, as the stock was down 0.9% at $193.40 on Thursday. The maker of Humira arthritis therapy added over 12% in the preceding seven ...

In this Healio video, Edward L. Barnes, MD, MPH, associate professor of medicine, co-director of the Multidisciplinary IBD Center and associate fellowship program director at the University of North ...

STAR-GLOBAL is an extension trial of the initial EU clinical trials investigating the long term safety and efficacy of ...

AbbVie’s stock nudged up 0.7% after Guggenheim lifted its price target, joining a parade of bullish analyst upgrades. Several ...

AbbVie wins FDA approval for Rinvoq in giant cell arteritis after strong Phase 3 results and a 57.2% year-over-year sales ...

The FDA has approved the Janus kinase inhibitor upadacitinib for the treatment of giant cell arteritis in adults, the first ...

All U.S. service members aboard the USS Harry S. Truman have been accounted for and are safe after a fighter jet, an F/A-18E ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The S&P 500 edged 0.1% higher on Monday, April 28, eking out a fifth straight winning session to kick off a week of key ...

Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.

One of the sources cited by Reuters said that international reference pricing presents an "existential threat to the industry ...